Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

K. L. Mahon, W. Qu, J. Devaney, C. Paul, L. Castillo, R. J. Wykes, M. D. Chatfield, M. J. Boyer, M. R. Stockler, G. Marx, H. Gurney, G. Mallesara, P. L. Molloy, L. G. Horvath, S. J. Clark

    Research output: Contribution to journalArticle

    Abstract

    Background: Glutathione S-transferase 1 (GSTP1) inactivation is associated with CpG island promoter hypermethylation in the majority of prostate cancers (PCs). This study assessed whether the level of circulating methylated GSTP1 (mGSTP1) in plasma DNA is associated with chemotherapy response and overall survival (OS).

    Methods: Plasma samples were collected prospectively from a Phase I exploratory cohort of 75 men with castrate-resistant PC (CRPC) and a Phase II independent validation cohort (n=51). mGSTP1 levels in free DNA were measured using a sensitive methylation-specific PCR assay. 

    Results: The Phase I cohort identified that detectable baseline mGSTP1 DNA was associated with poorer OS (HR, 4.2 95% CI 2.1-8.2; P<0.0001). A decrease in mGSTP1 DNA levels after cycle 1 was associated with a PSA response (P=0.008). In the Phase II cohort, baseline mGSTP1 DNA was a stronger predictor of OS than PSA change after 3 months (P=0.02). Undetectable plasma mGSTP1 after one cycle of chemotherapy was associated with PSA response (P=0.007).

    Conclusions: We identified plasma mGSTP1 DNA as a potential prognostic marker in men with CRPC as well as a potential surrogate therapeutic efficacy marker for chemotherapy and corroborated these findings in an independent Phase II cohort. Prospective Phase III assessment of mGSTP1 levels in plasma DNA is now warranted.

    Original languageEnglish
    Pages (from-to)1802-1809
    Number of pages8
    JournalBritish Journal of Cancer
    Volume111
    Issue number9
    DOIs
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Mahon, K. L., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R. J., Chatfield, M. D., Boyer, M. J., Stockler, M. R., Marx, G., Gurney, H., Mallesara, G., Molloy, P. L., Horvath, L. G., & Clark, S. J. (2014). Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer, 111(9), 1802-1809. https://doi.org/10.1038/bjc.2014.463